USFDA gives clearance to DeepTek.ai for its Chest X-ray AI solution

In Singapore, DeepTek’s US FDA-approved Platform – Augmento has been deployed as the National Radiology AI platform, boosting productivity and quality of care across all public hospitals.

USFDA, USFDA clearance, USFDA approval, medical devices, healthcare news,
In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential.

DeepTek.ai, a medical imaging AI company in India on Wednesday announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its revolutionary Chest X-ray AI solution – CXR Analyzer.

According to the company’s press statement, this advanced technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorizes, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations, the company claimed.

“Unlike traditional point AI solutions identifying a specific pathology, DeepTek’s Chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It’s compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful. This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases,” the company said in a statement.

In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential. The shortage of radiologists further emphasizes the role of AI in addressing this challenge.

“DeepTek CXR Analyzer v1.0 is a game-changer, reducing radiologist workload by an impressive 30-50%. With FDA clearance, we’re not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we’re unlocking a world of possibilities for improved outcomes across various medical specialties,” Dr. Amit Kharat, Co-Founder of DeepTek.ai, said in a statement.

DeepTek’s AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost, it claimed.

In Singapore, DeepTek’s US FDA-approved Platform – Augmento has been deployed as the National Radiology AI platform, boosting productivity and quality of care across all public hospitals. With its operations in Pune; DeepTek has about 200 members and has partners like TATA Capital, NTT DATA Japan and Shimadzu Asia Pacific, it added.

Get live Share Market updates, Stock Market Quotes, and the latest India News
This article was first uploaded on October nineteen, twenty twenty-three, at twelve minutes past one in the afternoon.
X